Statera Biopharma : Corporate Deck January 2022

I N V E S T O R

P R E S E N T A T I O N

January 12, 2022

Forward-Looking Statements

This presentation contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this presentation, including statements regarding the expected clinical development timeline for the Company's product candidates, future financial position , business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals, the impact of laws or regulations applicable to the Company, plans and objectives of management for future operations, are forward-looking statements. The words "anticipate," "believe," "continue," "should," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements on the current expectations about future events held by management. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. The Company's actual future results may differ materially from those discussed here for various reasons. The Company discusses many of these risks under the heading "Risk Factors" in the proxy statement/prospectus filed with the SEC on June 10, 2021, as updated by the Company's other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this presentation are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

2

Restoring Immune Health

Statera Biopharma, Inc.

intends to become a leader in developing and commercializing therapies that help restore dysfunctional immune systems to a state of homeostasis evolutionarily designed to fight cancers, emerging viruses and not result in autoimmune disease (overactive immune system)

www.staterabiopharma.com

3

Experienced Leadership

Michael	Taunia	Peter	Stephen	Cozette	Clifford Selsky M.D.,	Robert
Handley	Markvicka, Pharm.D.	Aronstam	Wilson, Ph.D.	McAvoy, J.D.	Ph.D.	Buckheit, Ph.D.
President & CEO	Chief Operating Officer	Chief Financial Officer	Chief Innovation Officer	CLO & CCO	Chief Medical Officer	Chief Technical Officer
Prior Management Experience		Notable Products From Prior Experience

4

Treatment Modalities are a Key Differentiator of Statera

Small Molecules	Biologics	Peptide &
Peptidomimetics

Chronic Inflammation &	Oncology/Hematology	Oncology
Autoimmunity
STAT-201 and STAT-205	Entolimod & GP532	STAT-401

Oral Formulation	Intravenous	Injectable
Oral (Tablet)

5